Comments
UK's NICE rejects Novartis asthma drug in change of tack
09.11.2012. | LONDON (Reuters) - Britain's health cost-effectiveness watchdog NICE plans to recommend against the use of Novartis's severe asthma drug Xolair, or omalizumab, after earlier endorsing it for adults only....
